Levi & Korsinsky notifies investors that it has commenced an investigation into Teleflex Incorporated (NYSE: TFX) concerning potential violations of the federal securities laws.
On February 27, 2025, Fierce Biotech published an article entitled "Teleflex plays musical chairs, plans company split amid €760M Biotronik cardiovascular deal." The article stated that "Teleflex has announced a plan to split its business into two separate independent companies-and it's setting up one of its future scions with a new portfolio of cardiovascular device assets, set to be acquired from Biotronik." Following this news, Teleflex's stock fell over 21% on the same day.
If you suffered a loss on your Teleflex Incorporated securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





